ResMed Inc. (RMD): Price and Financial Metrics

ResMed Inc. (RMD): $231.48

0.19 (+0.08%)

POWR Rating

Component Grades














  • Stability is the dimension where RMD ranks best; there it ranks ahead of 88.35% of US stocks.
  • The strongest trend for RMD is in Growth, which has been heading down over the past 179 days.
  • RMD's current lowest rank is in the Momentum metric (where it is better than 8.48% of US stocks).

RMD Stock Summary

  • With a market capitalization of $32,310,136,307, RESMED INC has a greater market value than 93.13% of US stocks.
  • With a one year PEG ratio of 500.71, RESMED INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.9% of US stocks.
  • Price to trailing twelve month operating cash flow for RMD is currently 92.01, higher than 95.81% of US stocks with positive operating cash flow.
  • Stocks that are quantitatively similar to RMD, based on their financial statements, market capitalization, and price volatility, are A, ALC, TEL, QGEN, and ABMD.
  • RMD's SEC filings can be seen here. And to visit RESMED INC's official web site, go to

RMD Valuation Summary

  • RMD's EV/EBIT ratio is 33.4; this is 209.26% higher than that of the median Healthcare stock.
  • Over the past 243 months, RMD's price/earnings ratio has gone up 13.2.

Below are key valuation metrics over time for RMD.

Stock Date P/S P/B P/E EV/EBIT
RMD 2022-09-01 9.0 9.6 41.2 33.4
RMD 2022-08-31 9.0 9.6 41.3 33.4
RMD 2022-08-30 9.0 9.6 41.2 33.3
RMD 2022-08-29 9.0 9.6 41.4 33.5
RMD 2022-08-26 9.0 9.6 41.5 33.6
RMD 2022-08-25 9.4 10.0 43.1 34.8

RMD Growth Metrics

    Its year over year price growth rate is now at 6.38%.
  • Its 4 year cash and equivalents growth rate is now at -54.86%.
  • Its 5 year cash and equivalents growth rate is now at -54.86%.
RMD's revenue has moved up $487,061,000 over the prior 15 months.

The table below shows RMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 3,578.127 351.147 779.437
2022-03-31 3,539.492 498.186 779.476
2021-12-31 3,443.759 577.025 521.983
2021-09-30 3,348.896 527.062 499.746
2021-06-30 3,196.825 736.718 474.505
2021-03-31 3,091.066 840.458 457.24

RMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RMD has a Quality Grade of C, ranking ahead of 68.39% of graded US stocks.
  • RMD's asset turnover comes in at 0.72 -- ranking 50th of 186 Medical Equipment stocks.
  • PEYE, MMSI, and SIEN are the stocks whose asset turnover ratios are most correlated with RMD.

The table below shows RMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.720 0.569 0.426
2021-06-30 0.691 0.575 0.410
2021-03-31 0.673 0.582 0.379
2020-12-31 0.676 0.582 0.342
2020-09-30 0.670 0.583 0.321
2020-06-30 0.672 0.581 0.300

RMD Price Target

For more insight on analysts targets of RMD, see our RMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $261.67 Average Broker Recommendation 1.91 (Hold)

RMD Stock Price Chart Interactive Chart >

Price chart for RMD

RMD Price/Volume Stats

Current price $231.48 52-week high $301.34
Prev. close $231.29 52-week low $189.40
Day low $228.91 Volume 132,694
Day high $233.28 Avg. volume 570,298
50-day MA $228.50 Dividend yield 0.76%
200-day MA $232.14 Market Cap 33.89B

ResMed Inc. (RMD) Company Bio

ResMed is a San DiegoCalifornia-based medical device company. It primarily provides cloud-connectable CPAP devices and masks for the treatment of sleep apnea, as well as devices and masks for treating chronic obstructive pulmonary disease (COPD), neuromuscular disease, and other respiratory-related conditions. It also provides a self-monitoring digital sensor and app for people who use inhalers to treat COPD or asthma via Propeller Health, which ResMed acquired in 2019. (Source:Wikipedia)  

RMD Latest News Stream

Event/Time News Detail
Loading, please wait...

RMD Latest Social Stream

Loading social stream, please wait...

View Full RMD Social Stream

Latest RMD News From Around the Web

Below are the latest news stories about RESMED INC that investors may wish to consider to help them evaluate RMD as an investment opportunity.

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.

Yahoo | August 30, 2022

Needham Remains a Hold on Resmed (RMD)

In a report released today, Michael Matson from Needham maintained a Hold rating on Resmed (RMD - Research Report). The company's shares closed yesterday at $240.85.Matson covers the Healthcare sector, focusing on stocks such as Resmed, Boston Scientific, and Cardiovascular Systems. According to TipRanks, Matson has an average return of 4.6% and a 51.93% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Resmed with a $192.02 average price target, a -20.27% downside from current levels. In a report released today, RBC Capital also downgraded the stock to a Hold with a $252.00 price target.

Howard Kim on TipRanks | August 12, 2022

Competitor Recall Continues To Show Opportunities For ResMed

ResMed Inc (NYSE: RMD) posted Q4 sales of $914.7 million, +4% Y/Y (+8% on a constant currency basis), beating the consensus of $912.97 million. Adjusted EPS reached $1.49, up from $1.35 a year ago. The company also increased its quarterly dividend to $0.44 from $0.42 per share. Keybanc reiterates the Overweight rating and price target of $276. The analyst says that after resetting near-term supply chain expectations, visibility appears to be increasing and management's tone seemed more optimisti

Yahoo | August 12, 2022

ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up

ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.

Yahoo | August 12, 2022

ResMed (RMD) Q4 2022 Earnings Call Transcript

Joining me on the call today are our chief executive officer, Mick Farrell, and chief financial officer, Brett Sandercock. Following our prepared remarks, we will host a Q&A session, and Mick and Brett will be joined by Rob Douglas, president and chief operating officer, and David Pendarvis, chief administrative officer and global general counsel.

Yahoo | August 12, 2022

Read More 'RMD' Stories Here

RMD Price Returns

1-mo -2.06%
3-mo 11.22%
6-mo -2.38%
1-year -21.58%
3-year 75.49%
5-year 205.58%
YTD -10.62%
2021 23.41%
2020 38.33%
2019 37.85%
2018 36.38%
2017 39.06%

RMD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RMD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9278 seconds.